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Abstract
AIM: To determine the mutation status of human 
telomerase reverse transcriptase gene (TERT) promoter 
region in hepatocellular carcinoma (HCC) from different 
geographical regions.
METHODS: We analyzed the genomic DNA sequences 
of 59 HCC samples comprising 15 cell lines and 44 
primary tumors, collected from patients living in Asia, 
Europe and Africa. We amplified a 474 bp DNA fragment 
of the promoter region of TERT gene including the 
1295228 and 1295250 sequence of chromosome 5 by 
using PCR. Amplicons were then sequenced by Sanger 
technique and the sequence data were analyzed with 
by using DNADynamo software in comparison with wild 
type TERT gene sequence as a reference.
RESULTS: The TERT mutations were found highly 
frequent in HCC. Eight of the fifteen tested cell lines 
displayed C228T mutation, and one had C250T mutation 
with a mutation frequency up to 60%. All of the 
mutations were heterozygous and mutually exclusive. 
Ten out of forty-four tumors displayed C228T mutation, 
and additional five tumors had C250T mutation providing 
evidence for mutation frequency of 34% in primary 
tumors. Considering the geographic origins of HCC tumors 
tested, TERT promoter mutation frequencies were higher 
in African (53%), when compared to non-African (24%) 
tumors (P  = 0.056). There was also a weak inverse 
correlation between TERT promoter mutations and 
murine double minute 2 single nucleotide polymorphism 
309 TG polymorphism (P  = 0.058). Mutation frequency 
was nearly two times higher in established HCC cell 
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lines (60%) compared to the primary tumors (34%).
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mutational targets in liver cancer, and hepatocellular 
carcinogenesis is highly associated with the loss of 
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Core tip: Our study demonstrated that telomerase 
reverse transcriptase (TERT) promoter mutations are 
present in hepatocellular carcinomas (HCCs) from 
different geographical regions, and the highest frequency 
was observed in tumors from Africa. These mutations 
occur both primarily as C228T mutation and as C250T 
mutation. These results also provide evidence for TERT 
mutations as a common trait of HCC regardless of their 
geographical location.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of  the most 
common and fatal cancers with a heterogeneous incidence 
throughout different regions of  the world[1]. HCC, whose 
incidence has been vigorously increasing in western coun­
tries, has the highest incidence in China, Middle Africa, 
and Japan. Epidemiology of  HCC differs among different 
geographical regions. Hepatitis B and C are the main 
risk factors in Asia and Africa while alcohol intake is the 
main driving force in Europe and the United States[2]. 
Overall survival rate of  HCC patients is very low due to 
inefficient treatment options. HCC is resistant to most of  
the conventional therapies, thus the only plausible treatment 
is liver transplantation that is restricted to early­diagnosed 
cases[3]. In order to provide a more effective therapeutic 
approach to HCC patients, genetic mechanisms underlying 
liver carcinogenesis have been studied for years; however, 
most of  the mutations identified so far are “loss-of-function” 
type, thus they are not suitable to be used for targeted 
therapy[4]. The only molecularly targeted drug for HCC 
treatment is Sorafenib whose efficacy is not satisfactory[5].
Tumor cells need to overcome the telomere shortening 
problem, one of  the most crucial obstacles during the 
transformation process. This can be achieved either by up­
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regulating telomerase activity or with alternative lengthening 
of  telomeres[6]. Integration of  hepatitis B viral DNA 
into the telomerase reverse transcriptase (TERT) gene is 
observed in HCC patients with hepatitis B viral (HBV) 
infection and considered found as one of  the paths to 
increase telomere length[7­9]. However, there are many 
HCC cases without HBV involvement and in which 
telomere length is still an issue for those. Recently, many 
groups reported the presence of  two frequent mutations 
in TERT promoter region in different tumors including 
HCC[10­16]. These promoter mutations are claimed to 
upregulate the TERT transcription by creating a binding 
site for ETS (E­twenty six)[10] and ternary complex factor 
(TCF) transcription factors[11]. Reported HCC tumors with 
TERT promoter mutations were from United States[12] 
and France[15] and mutation frequencies were 44% and 
59%, respectively. Highly frequent TERT mutations may 
serve not only as novel diagnostic markers but also as and 
potential therapeutic targets for HCC. However, it is still 
unknown whether TERT promoter mutations occur in 
diverse HCCs worldwide, regardless of  their geographical 
origin. As these tumors occur less frequently in western 
populations, but quite commonly then in Asian and African, 
TERT promoter status in Asian and African HCC patients 
is worth to know. In this study, we analyzed 15 HCC cell 
lines, as well as 44 HCC tumors from three different 
continents in search for two hotspot mutations in TERT 
promoter.
MATERIALS AND METHODS
Ethics and patient tissues
We used archival HCC tumor DNA samples (n = 44) that 
have been described previously in terms of  hepatitis B 
viral DNA testing, TP53 mutations and murine double 
minute 2 (MDM2) polymorphism[17,18].
Cell lines
Huh7, HepG2, Hep3B, Hep40, PLC/PRF/5, FOCUS, 
Mahlavu, FLC4, and SK­HEP­1 cells were cultured in 
Dulbecco’s modified Eagles medium, whereas SNU182, 
SNU387, SNU398, SNU423, SNU449, and SNU475 cell 
lines are grown in RPMI. Both media were supplemented 
with 10% fetal calf  serum, 2 mmol/L L­glutamine, 1
× non essential amino acids, and 100 units of  penicillin/
streptomycin (all from Life Technologies™). Cells were 
grown up to 70% confluency before genomic DNA 
extraction.
Mutation analysis by nucleic acid sequencing
Genomic DNA samples were isolated by using Purelink 
Genomic DNA Kit (Life Technologies™) according to 
manufacturer’s instructions, then DNA concentrations 
were measured with Nanodrop Spectrometer (Thermo 
Scientific). 100 ng of  genomic DNA was used to amplify 
a 474 bp region of  TERT promoter flanking hotspot 
mutations that are found at positions 1295228 and 1295250 
of  chromosome 5 by using AccuPrime GC­rich DNA 
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Table 1  Telomerase reverse transcriptase promoter mutations 
in hepatocellular carcinoma cell lines
polymerase kit (Life Technologies™) with forward primer 
5’­ACGAACGTGGCCAGCGGCAG­3’ and reverse 
primer 5’­ CTGGCGTCCCTGCACCCTGG­3’[11]. 
Amplicons were sequenced with Sanger technique, and data 
were analyzed with DNADynamo software (BlueTractor 
Software Ltd) by comparing TERT sequence from UCSC 
Genome Browser as a reference.
Statistical analysis
Fisher exact test was used to compare statistical differences 
(P­values; one­tailed) among clinical samples holding and 
lacking TERT promoter mutation using Wassar Statistics 
Tool available online (http://vassarstats.net). A P­value of  
less than 0.05 was considered to be significant.
RESULTS
TERT promoter mutations are frequently observed in 
hepatocellular carcinoma cell lines
We tested a panel of  15 HCC cell lines composed of  
six epithelial­like (Huh7, HepG2, Hep3B, Hep40, PLC/
PRF/5, and FLC4) and nine mesenchymal­like (FOCUS, 
Mahlavu, SNU182, SNU387, SNU398, SNU423, SNU449, 
and SNU475, SKHEP1) cell types[19] for mutations at 
TERT gene promoter. Nine cell lines carried C228T 
mutation but only one cell line, Mahlavu, carried C250T 
mutation; all mutations were heterozygous (Table 1). 
Two examples of  sequence chromatograms representing 
C228T and C250T mutations are given in Figure 1. In 
sum, 67% (10 out of  15) of  HCC cell lines displayed a 
TERT promoter mutation. In all HCC cell lines tested, 
C228T and C250T mutations were found in a mutually 
exclusive manner. Both epithelial­like and mesenchymal­
like cells had these mutations with similar frequencies (4 
out of  6, and 6 out of  9 respectively). We concluded that 
TERT promoter mutations occur frequently in HCC cell 
lines, regardless of  their differentiation status.
TERT promoter mutations in primary hepatocellular 
carcinoma tumors
To determine TERT promoter mutation frequency in 
HCC tumors, we tested an archival collection of  44 HCC 
tumor DNAs (Table 2) collected from different countries 
around the world including Japan (11 patients), China 
(8), Germany (7), France (2), Israel (1), Mozambique (6), 
Transkei (4), Lesotho (2), Swaziland (1), and South Africa 
(2). Based on tumor viral DNA testin[16,17] the etiology 
for 23 out of  44 (52.3%) of  these tumors was hepatitis 
B virus infection. The etiology of  other tumors was 
unknown. We identified 15 mutations in 44 tumors, 10 of  
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Figure 1  Sequence chromatograms are representing telomerase reverse transcriptase promoter mutations. Locations of (C228T) and (C250T) mutations are 















Figure 2  Geographic distribution of telomerase reverse transcriptase promoter mutations. Tumor samples from Africa have the highest mutation rate (53%), 
followed by European samples with 30%, and Asian samples with a rate of only 21%. WT: Wild type.
Cell lines TERT promoter status
Epitheliel-like
   Huh7 C228T
   HepG2 C228T
   Hep3B C228T
   FLC4 C228T
   Hep40 Wild-type
   PLC/PRF/5 Wild-type
Mesenchymal-like
   FOCUS C228T
   SNU387 C228T
   SNU398 C228T
   SNU423 C228T
   SNU475 C228T
   Mahlavu C250T
   SNU182 Wild-type
   SNU449 Wild-type
   SKHEP1 Wild-type
TERT: Telomerase reverse transcriptase promoter.
5%
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Table 2  Telomerase reverse transcriptase promoter mutation analysis of hepatocellular carcinoma tumors
which were C228T and the other 5 were C250T mutations. 
C228T mutations (23%) were again more frequent than 
C250T mutations (11%) and they were mutually exclusive, 
as observed in HCC cell lines (Table 2).
Figure 2 displays the distribution of  TERT mutations 
in different continents. Tumors from Africa with the 
highest mutation frequency (53%) were followed by tumors 
from Europe (30%) and Asia (21%), respectively. We 
were not able to test whether these mutations were germ­
line or somatically acquired, however, all reported C228T 
and C250T mutations in HCC were acquired somatic 
mutations[12,15]. Thus; we assume that mutations reported 
here are also somatic.
Association of TERT promoter mutations with 
geographical origin of tumors and MDM2 SNP 309 
polymorphism
Table 3 compares patient characteristics such as gender, 
age, geographical status, tumor HBV DNA and TP53 
mutation as well as patient MDM2 single nucleotide 
polymorphism (SNP) 309 status with the mutational status 
of  TERT promoter. There was no significant difference 
found in patient gender and age, but a weak association (P 
= 0.056) was found in geographical origin. Tumors from 
African patients displayed TERT promoter mutations 
two­fold more frequently (53%) than non­African patients 
(24%). Tumors with HBV DNA displayed less frequent 
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Country TERT mutations p53 mutations MDM2 HBV Stage
C228T C250T Codon Amino Acid change SNP 309
Japan C228T WT 6 bp del Del (AGCTAC) G/G Minus1 Unknown
Japan C228T WT WT T/G Minus1 Unknown
Japan C228T WT WT T/G Minus1 Unknown
Japan WT C250T WT G/G Minus1 Unknown
Japan WT WT WT T/G Minus1 Unknown
Japan WT WT WT T/G Minus1 Unknown
Japan WT WT WT T/G Minus1 Unknown
Japan WT WT WT T/G Minus1 Unknown
Japan WT WT WT T/G plus1 Unknown
Japan WT WT WT G/G Minus1 Unknown
Japan WT WT WT T/G Minus1 Unknown
China WT WT 281 C > A Asp > Glu T/T plus1 Unknown
China WT WT WT G/G Plus1 Unknown
China WT WT WT T/G Plus1 Unknown
China WT WT WT T/T Plus1 Unknown
China WT WT WT G/G Plus1 Unknown
China WT WT WT T/T Plus1 Unknown
China WT WT WT G/G Plus2 Unknown
China WT WT WT G/G plus1 Unknown
Israel WT WT WT T/G Minus1 Unknown
Mozambique C228T WT 157 G > T Val > Phe T/T Plus1 Late
Mozambique C228T WT WT T/T Plus2 Late
Mozambique WT C250T WT T/T Plus2 Late
Mozambique WT C250T 249 G > T Arg > Ser T/T Minus1 Early
Mozambique WT WT WT T/T Plus2 Late
Mozambique WT WT 249 G > T Arg > Ser T/T Plus1 Late
Transkei C228T WT WT T/T NT Late
Transkei C228T WT WT T/T NT Late
Transkei WT WT WT T/T NT Early
Transkei WT WT WT T/T Plus1 Late
Lesotho WT C250T WT T/T Plus2 Early
Lesotho WT WT WT T/G Plus2 late
Swaziland WT WT WT T/T Plus Early
South Africa C228T WT WT T/T Plus2 Late
South Africa WT WT WT T/G Plus2 Late
Germany C228T WT WT G/G Minus1 Metastasis
Germany C228T WT 273 C > T Arg > Cys T/T Minus1 HCC
Germany WT C250T WT G/G Plus2 HCC
Germany WT WT WT G/G Minus1 Unknown
Germany WT WT WT G/G Minus1 Metastasis
Germany WT WT WT T/T Plus2 Unknown
Germany WT WT WT T/G Plus2 HCC
France WT WT WT T/G Minus1 Unknown
France WT WT WT T/G Minus1 Unknown
1means reference 17; 2means reference 18. The collection of tumor samples used for telomerase reverse transcriptase (TERT) promoter mutation analysis 
is displayed together with complementary data. WT: Wild type; Del: Deletion; HCC: Hepatocellular carcinoma; SNP: Single nucleotide polymorphism; 
MDM2: Murine double minute 2; HBV: Hepatitis B viral.
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Table 3  Characteristics of the patients according to telomerase reverse transcriptase promoter mutation status  n  (%)
TERT promoter mutations (26%) as compared to HBV­
negative tumors (39%), but the difference did not reach to 
a significance (P = 0.295). Similarly, tumors with wild­type 
TP53 displayed less frequent TERT promoter mutations 
(29%) as compared to those with a mutation (50%). 
However, this difference did not reach to a significant 
level (P = 0.280). In contrast, we found a week association 
between TERT promoter mutations and MDM2 SNP 309 
TG polymorphism (P = 0.058). Patients with SNP309 
TT polymorphism displayed 44% TERT promoter 
mutation, in contrast to those with TG polymorphism 
which displayed only 13% TERT promoter mutations. 
Indeed, TERT promoter mutations were over 3­fold more 
frequent in patients with MDM2 SNP 309 TT status, than 
those with a TG status.
DISCUSSION
The TERT gene, encoding the catalytic subunit of  telo­
merase reverse transcriptase enzyme, is a limiting factor 
for unlimited proliferation of  most human somatic cells 
including hepatocytes. Lack of  TERT gene expression 
in these cells leads to a progressive erosion of  telomeres 
during successive cell divisions culminating with a permanent 
cell cycle arrest when telomere DNA reaches a critically 
short stature. Cancer cells such as HCC cells overcome 
this arrest by reactivating TERT gene expression with 
ill­known mechanisms. TERT reactivation is so far the 
most frequently observed (80%­90%) aberration in HCC 
tumors[20,21]. Several mechanisms have been reported for the 
activation of  TERT expression in cancer cells, including 
myc and Wnt/β­catenin signaling­mediated activation[22­24], 
alternative splicing, and epigenetic alterations[25,26]. 
Whether these mechanisms are involved in hepatocellular 
carcinogenesis is still unknown.
TERT reactivation is associated with HBV DNA inte­
gration near the TERT gene in rare cases of  HCC, 
providing a clue about viral reactivation of  TERT 
expression[7]. In addition, TERT promoter mutations 
have been reported recently as frequent events in some 
cancers such as melanoma, sarcomas, urothelial carcinoma, 
bladder cancer, glioblastoma, thyroid cancer, and HCC[10­16]. 
Although it is not clear yet whether such mutations are 
necessary and sufficient for TERT reactivation in cancer 
cells, it appears that somatic mutations of  TERT promoter 
are among the most frequent aberrations observed in 
some tumor types. Our studies in HCC cell lines reiterate 
this striking finding. With 60% frequency, TERT mutation 
is the most frequent mutational event observed in these 
cell lines together with TP53 mutations so far[27]. Thus, 
it is very likely that TERT promoter mutations facilitate 
the establishment of  HCC cell lines by overcoming 
telomere shortening during in vitro culture. We have 
found similar mutation frequencies for both epithelial­
like and mesenchymal­like cell lines suggesting that 
mutagenesis of  the TERT promoter is independent of  the 
differentiation status of  the cell lines. Early HCCs display 
epithelial like morphology whereas advanced HCCs may 
display mesenchymal­like morphology associated with 
epithelial to mesenchymal transition that is often observed 
during tumor progression[28,29]. Our findings suggest that 
TERT mutations are early events during hepatocellular 
carcinogenesis in confirmation with a recent report[15]. 
The mutations observed in cell lines are the same type of  
mutations observed in primary tumors. This suggests that 
cell line mutations did not occur spontaneously during cell 
culture. Their high frequency may indicate that tumor cells 
with such mutations are established more easily.
TERT promoter mutations that are observed in 
34% of  primary HCC tumors are quite high, albeit less 
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Variable Overall series TERT promoter mutated TERT promoter non-mutated P  value
(n  = 44) (n  = 15) (n  = 29)
Gender
   Male 27 10 17 0.2059
   Female   1   1   0
Age
   ≥ 60 yr   9   3 (33)   6 (67) 0.6547
   < 60 yr 19   8 (42) 11 (58)
Geographical origin
   African 15   8 (53)   7 (47) 0.0528
   Non-African 29   7 (24) 22 (76)
HBV DNA
   Positive 23   6 (26) 17 (74) 0.2950
   Negative 18   7 (39) 11 (61)
TP53
   Mutated   6   3 (50)   3 (50) 0.6315
   Wild-type 38 11 (29) 27 (71)
MDM2 SNP 309
   TT 18   8 (44) 10 (56)
   TG 15   2 (13) 13 (87) 0.0528 (vs TT)
   GG 11   4 (36)   7 (64)
TERT: Telomerase reverse transcriptase; SNP: Single nucleotide polymorphism; MDM2: Murine double minute 2; HBV: Hepatitis B viral.
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frequent than those observed in cell lines. This lower 
frequency in tumors may be expected because of  the 
potential bias due to a selective advantage during cell 
culture as stated above. Additionally, heterozygous TERT 
promoter mutations may be more difficult to detect due 
to the contamination of  tumor DNA with the DNA 
coming from non­cancer cells into tumor tissues. Despite 
these limitations, the existence of  TERT promoter 
mutations in at least one­third of  primary tumors indicates 
that this gene is one of  the most frequent targets for 
mutation in liver cancer. Our recently published findings 
pinpointed TERT as a critical gene involved in HCC cell 
immortality, which itself  is viewed as a central mechanism 
of  hepatocellular carcinogenesis in humans[30,31]. This 
present study, together with a recent study[15] clearly 
establishes that TERT promoter mutation is a hallmark 
of  liver cancer. Our findings provide further evidence for 
a global incidence of  TERT promoter mutations in liver 
cancer regardless of  their geographical origin. Moreover, 
we provide preliminary evidence for a higher frequency 
of  these mutations in patients from Africa. Thus TERT 
mutations restricted to two hotspots at its promoter, are 
universal markers for liver cancer and thus they may serve 
as easy cancer biomarkers in high risk populations such as 
those chronically infected with hepatitis viruses, as well as 
cirrhosis. Finally, higher manifestation of  TERT promoter 
mutations in HCC patients with MDM2 SNP309 TG status 
strongly suggests that there is a cross talk between TP53-
MDM2 axis and TERT functions in liver cancer. Further 
research is needed to confirm these initial observations.
In conclusion, TERT promoter mutations that are 
widely observed in liver cancers from around the world 
provide sufficient evidence for the critical role of  telomere 
biology and cellular immortality in these cancers.
COMMENTS
Background
Hepatocellular carcinoma (HCC) is one of the most fatal cancers over the world 
with an increasing incidence in western countries, so it is of great importance 
to reveal genetic mechanisms that may play an important role in liver tumor 
formation. Telomeres are repetitive DNA sequences found at both ends of each 
chromosome. In normal somatic cells, they get shorter after each cell division 
and cells can no longer divide when telomere length becomes too short. Tumor 
cells require mechanisms to overcome telomere shortening problem to be 
able to divide infinitely. One way to solve telomere shortening problem is to 
reactivate telomerase reverse transcriptase (TERT) to synthesize telomeric 
DNA and prevent telomeres from shortening. TERT may be activated via 
promoter mutations. Here we determine mutation status of TERT promoter in 
established liver cancer cell lines and patient tumor samples.
Research frontiers
TERT promoter mutations have first been defined in melanoma and they 
are claimed to create new binding sites for specific transcription factors and 
increase TERT expression. This may be used by tumor cells as a mechanism 
to overcome telomere shortening problem so it is important to show the 
presence of the same mutations in the promoter region of TERT and determine 
their frequencies in HCC. Deficiencies of early diagnosis and systemic therapy 
of liver cancer are the major causes of its high mortality. Screening of TERT 
promoter status may help early diagnosis of tumor formation in patients with 
chronic liver disease. In addition, targeting of TERT promoter mutations may 
open new horizons for specific therapies of liver cancer.
Innovations and breakthroughs
Telomerase reactivation is common to liver cancer samples, and TERT 
promoter mutations have been reported recently. Tumor samples were collected 
from hospitals from counties such as France and United States, where liver 
cancer is not a major disease contrary to some other countries located in Asia 
(China and Japan) and Africa (southern African countries) with a very high 
incidence. Thus, it was not clear how common TERT promoter mutations were 
over the world, especially in Africa and Asia. In this present study, we tried to 
show that TERT promoter mutations are common in hepatocellular carcinoma 
(HCC), regardless of geographical location. Moreover, this research showed 
that HCCs from Africa are more likely to carry TERT promoter mutations, in 
comparison with Non-African tumors.
Applications
The high frequency of TERT promoter mutations resulting from the present 
study suggests that these mutations are critical or may be necessary for liver 
tumor formation. Therefore, they can be used for diagnostic or prognostic 
purposes for patient care. Furthermore, if such mutations are causing tumor-
specific reactivation of telomerase activity, they may serve as tumor-selective 
targets for novel therapies.
Terminology
Hepatocellular carcinoma is a primary liver cancer. Telomeres are DNA 
sequences located on the tips of chromosomes. TERT gene encodes for an 
enzyme responsible for the synthesis of telomeric DNA.
Peer review
The authors determined mutation status of human TERT promoter region in 
HCCs from different geographical regions. Although some articles have the 
same scope but the new item is the effect of different geographical locations, 
the article is well-organized and is perfectly written.
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